Robert Bachman

880 total citations
9 papers, 725 citations indexed

About

Robert Bachman is a scholar working on Oncology, Psychiatry and Mental health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert Bachman has authored 9 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 4 papers in Psychiatry and Mental health and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert Bachman's work include Migraine and Headache Studies (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Robert Bachman is often cited by papers focused on Migraine and Headache Studies (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Robert Bachman collaborates with scholars based in United States, Taiwan and Finland. Robert Bachman's co-authors include Christopher Assaid, David W. Dodick, Joy Yang Ge, Christopher Lines, David Hewitt, Tony W. Ho, David Michelson, Richard B. Lipton, Tiffini Voss and Sheena K. Aurora and has published in prestigious journals such as Journal of Clinical Oncology, Lung Cancer and Headache The Journal of Head and Face Pain.

In The Last Decade

Robert Bachman

9 papers receiving 703 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Bachman United States 9 450 306 216 171 131 9 725
Barbara Teter United States 13 72 0.2× 413 1.3× 105 0.5× 48 0.3× 26 0.2× 28 656
Wenjun Meng China 13 59 0.1× 53 0.2× 45 0.2× 172 1.0× 50 0.4× 45 503
Anna Dzagnidze Germany 9 408 0.9× 317 1.0× 96 0.4× 150 0.9× 23 0.2× 9 569
Thuy Vu United States 12 231 0.5× 153 0.5× 18 0.1× 116 0.7× 10 0.1× 13 654
Lars Lykke Thomsen Denmark 8 225 0.5× 92 0.3× 17 0.1× 140 0.8× 35 0.3× 12 423
Dirk Pleimes Germany 11 69 0.2× 496 1.6× 76 0.4× 34 0.2× 22 0.2× 28 659
Dongtai Chen China 12 156 0.3× 20 0.1× 102 0.5× 38 0.2× 40 0.3× 28 546
Takeshi Yanagisawa Japan 11 109 0.2× 65 0.2× 14 0.1× 39 0.2× 99 0.8× 23 385
Megumu Tanaka Japan 15 82 0.2× 19 0.1× 67 0.3× 49 0.3× 44 0.3× 27 454
Maya Horowitz Israel 2 337 0.7× 13 0.0× 191 0.9× 46 0.3× 71 0.5× 3 550

Countries citing papers authored by Robert Bachman

Since Specialization
Citations

This map shows the geographic impact of Robert Bachman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Bachman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Bachman more than expected).

Fields of papers citing papers by Robert Bachman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Bachman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Bachman. The network helps show where Robert Bachman may publish in the future.

Co-authorship network of co-authors of Robert Bachman

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Bachman. A scholar is included among the top collaborators of Robert Bachman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Bachman. Robert Bachman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Gadgeel, Shirish M., James Stevenson, Corey J. Langer, et al.. (2018). Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 125. 273–281. 68 indexed citations
2.
Gadgeel, Shirish M., James Stevenson, Corey J. Langer, et al.. (2016). Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.. Journal of Clinical Oncology. 34(15_suppl). 9016–9016. 74 indexed citations
3.
Voss, Tiffini, Richard B. Lipton, David W. Dodick, et al.. (2016). A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 36(9). 887–898. 191 indexed citations
4.
Pardoe, Heath, Robert Bachman, Catherine Shain, et al.. (2015). Phenotypic and imaging features of FLNA-negative patients with bilateral periventricular nodular heterotopia and epilepsy. Epilepsy & Behavior. 51. 321–327. 11 indexed citations
5.
Papadimitrakopoulou, Vassiliki A., Amita Patnaik, Hossein Borghaei, et al.. (2015). Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.. Journal of Clinical Oncology. 33(15_suppl). 8031–8031. 31 indexed citations
6.
Patnaik, Amita, Mark A. Socinski, Matthew A. Gubens, et al.. (2015). Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.. Journal of Clinical Oncology. 33(15_suppl). 8011–8011. 61 indexed citations
7.
Ho, Tony W., Eric Pearlman, Donald W. Lewis, et al.. (2012). Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia. 32(10). 750–765. 54 indexed citations
8.
Hewitt, David, Eric Pearlman, Mirja Hämäläinen, et al.. (2012). Long‐Term Open‐Label Safety Study of Rizatriptan Acute Treatment in Pediatric Migraineurs. Headache The Journal of Head and Face Pain. 53(1). 104–117. 10 indexed citations
9.
Hewitt, David, Sheena K. Aurora, David W. Dodick, et al.. (2011). Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 31(6). 712–722. 225 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara Teter Breakdown of academic impact, for papers by Wenjun Meng Breakdown of academic impact, for papers by Anna Dzagnidze Breakdown of academic impact, for papers by Thuy Vu Breakdown of academic impact, for papers by Lars Lykke Thomsen Breakdown of academic impact, for papers by Dirk Pleimes Breakdown of academic impact, for papers by Dongtai Chen Breakdown of academic impact, for papers by Takeshi Yanagisawa Breakdown of academic impact, for papers by Megumu Tanaka Breakdown of academic impact, for papers by Maya Horowitz
Rankless by CCL
2026